<p>Balb/c mice were immunized according to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072217#pone-0072217-t001" target="_blank">Table 1</a>. Five weeks after the second immunization, the mice were challenged with 250 PFU IAV (PR/8/34). The weight loss of each animal was monitored daily and the means and SEM (n = 5–6) are indicated for each group up to day 6 post challenge (<b>A</b>). At day 6, viral loads in lung homogenates (vRNA copies/ml) were measured by qRT-PCR. Each animal is represented by one dot and the means of each group are marked by the line. The dotted line indicates the detection limit (428 copies/ml) (<b>B</b>). (p<0.05): <b>*</b> vs. naïve; <b><sup>#</sup></b> vs. (F)<sup>hi</sup> (1 way-ANOVA, T...
<p>Mouse groups were immunized with 1203HA, 05HA, H5b, H7HA, H9HA, H7H9b, H5b+H7H9b or ΔE1E3 twice a...
<p>At 18 days following the last immunization, all mice in study group B were intranasally challenge...
<p>Mice (n = 6/groups) were immunized subcutaneously on day 0 and 28. All groups were challenged int...
<p>Balb/c mice were immunized according to <a href="http://www.plosone.org/article/info:doi/10.1371/...
<p>A–B: Protection against A/California/04/2009 virus challenge. Mice intramuscularly immunized with...
<p>Mice were challenged one month after vaccination (0.5 µg PZQ/0.1 µg antigen). (A) Viral loads in ...
<p>Mice were immunized i.n. or s.l. with 3M2eC (10 ug) plus CT (2 ug) on days 0 and 14 and challenge...
<p>Four groups of mice were infected with a non-lethal dose of influenza (0.33×MLD<sub>50</sub>) as ...
<p>Six-week-old female BALB/c mice (n = 6) were immunized twice with 10 ug of 3M2eC protein plus 2 u...
<p>The immunized mice were intranasally challenged with the reassortant RG2 (clade 2.1) or NIBRG23 (...
<p>(A–C) Groups of 9 BALB/c mice were vaccinated with 10<sup>10</sup> vp/mouse of PAV3-HA (▵), AdHu5...
<p>(A) Study design: BALB/c mice were vaccinated intranasally with the pressurized H3N8 at the indic...
<p>Mouse groups were immunized with H1HA, H5b+H7H9b+H1HA, or ΔE1E3 twice at four week intervals. Fou...
<p>At week 5, mice vaccinated with clade 2-dervied vaccines were challenged intranasally with a leth...
<p>(<b>a</b>) Schematic diagram of the immunization and challenge studies. (<b>b</b>) At 2 weeks aft...
<p>Mouse groups were immunized with 1203HA, 05HA, H5b, H7HA, H9HA, H7H9b, H5b+H7H9b or ΔE1E3 twice a...
<p>At 18 days following the last immunization, all mice in study group B were intranasally challenge...
<p>Mice (n = 6/groups) were immunized subcutaneously on day 0 and 28. All groups were challenged int...
<p>Balb/c mice were immunized according to <a href="http://www.plosone.org/article/info:doi/10.1371/...
<p>A–B: Protection against A/California/04/2009 virus challenge. Mice intramuscularly immunized with...
<p>Mice were challenged one month after vaccination (0.5 µg PZQ/0.1 µg antigen). (A) Viral loads in ...
<p>Mice were immunized i.n. or s.l. with 3M2eC (10 ug) plus CT (2 ug) on days 0 and 14 and challenge...
<p>Four groups of mice were infected with a non-lethal dose of influenza (0.33×MLD<sub>50</sub>) as ...
<p>Six-week-old female BALB/c mice (n = 6) were immunized twice with 10 ug of 3M2eC protein plus 2 u...
<p>The immunized mice were intranasally challenged with the reassortant RG2 (clade 2.1) or NIBRG23 (...
<p>(A–C) Groups of 9 BALB/c mice were vaccinated with 10<sup>10</sup> vp/mouse of PAV3-HA (▵), AdHu5...
<p>(A) Study design: BALB/c mice were vaccinated intranasally with the pressurized H3N8 at the indic...
<p>Mouse groups were immunized with H1HA, H5b+H7H9b+H1HA, or ΔE1E3 twice at four week intervals. Fou...
<p>At week 5, mice vaccinated with clade 2-dervied vaccines were challenged intranasally with a leth...
<p>(<b>a</b>) Schematic diagram of the immunization and challenge studies. (<b>b</b>) At 2 weeks aft...
<p>Mouse groups were immunized with 1203HA, 05HA, H5b, H7HA, H9HA, H7H9b, H5b+H7H9b or ΔE1E3 twice a...
<p>At 18 days following the last immunization, all mice in study group B were intranasally challenge...
<p>Mice (n = 6/groups) were immunized subcutaneously on day 0 and 28. All groups were challenged int...